Maternal Metabolic Control and Perinatal Outcome in Women With Gestational Diabetes Mellitus Treated With Lispro or Aspart Insulin | Zendy

Graziano Di Cianni | Zendy; Laura Volpe | Zendy; Alessandra Ghio | Zendy; Cristina Lencioni | Zendy; Ilaria Cuccuru | Zendy; Luca Benzi | Zendy; Stefano Del Prato | Zendy

Open Access

Maternal Metabolic Control and Perinatal Outcome in Women With Gestational Diabetes Mellitus Treated With Lispro or Aspart Insulin

Author(s) -

Graziano Di Cianni,

Laura Volpe,

Alessandra Ghio,

Cristina Lencioni,

Ilaria Cuccuru,

Luca Benzi,

Stefano Del Prato

Publication year - 2007

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc06-2586

Subject(s) - medicine , insulin lispro , gestational diabetes , diabetes mellitus , insulin aspart , metabolic control analysis , insulin , pregnancy , obstetrics , endocrinology , gestation , human insulin , postprandial , genetics , biology

Gestational diabetes mellitus (GDM) is associated with increased risk of maternal and neonatal morbidity with macrosomia being the most common neonatal complication (1). The risk of macrosomia and/or disproportionate fetal growth is closely related to 1-h postprandial glucose concentration (2).Therefore, the treatment of GDM should be aimed at normalizing maternal glycemia including the early postprandial response. Insulin therapy is needed whenever strict normoglycemia cannot be achieved by medical nutritional therapy alone (3). Because of their pharmacokinetic properties, short-acting insulin analogs (Insulin Aspart [ASP] and Insulin Lispro [LIS]) could be more effective in pregnancy than human regular insulin (HI) (4). Nevertheless, data …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research